Doriano Fabbro - Concepedia

Author

Doriano Fabbro

Also Known As

D FABBRO, D Fabbro, D. FABBRO, D. Fabbro, Doriano FABBRO, Doriano Fabbro, Doriano Fabbro (156139), Fabbro Doriano, Fabbro, D, Fabbro, D.

349

Publications

29.5K

Citations

H-Index

167

Concepts

All Affiliations

Novartis (Switzerland)Novartis Institutes for BioMedical Research PIQUR Therapeutics (Switzerland)University of Basel Dana-Farber Cancer Institute

About

Doriano Fabbro is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	57	101	16.4K
2	Natural Sciences	28	33	5.8K
3	Health Sciences	9	9	736
4	Engineering	3	3	85
5	Humanities	1	1	10

Doriano Fabbro

168

Publications

25.3K

Citations

H-Index

Page 1

	Year	Citations
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY Simon D Harding, Joanna L Sharman, Elena Faccenda, Nucleic Acids Research Clinical ImmunologyNew LigandsImmunodeficienciesImmunologySystem Pharmacology	2017	1.6K
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Ellen Weisberg, Paul W. Manley, Werner Breitenstein, Cancer Cell Molecular PharmacologyMutant Bcr-ablMedicineSelective InhibitorMolecular Biology	2005	1.5K
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, Molecular Cancer Therapeutics	2008	1.1K
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands Christopher Southan, Joanna L Sharman, Helen E. Benson, Nucleic Acids Research Drug TargetQuantitative PharmacologyMolecular BiologyBioinformatics DatabaseMolecular Pharmacology	2015	1K
The Concise Guide to PHARMACOLOGY 2015/16: Enzymes S P H Alexander, Doriano Fabbro, Eamonn Kelly, British Journal of Pharmacology	2015	603
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes S P H Alexander, Doriano Fabbro, Eamonn Kelly, British Journal of Pharmacology Other Ion ChannelsDrug TargetSystem PharmacologySystems PharmacologyMolecular Pharmacology	2017	597
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412 Ellen Weisberg, Christina Boulton, Louise Kelly, Cancer Cell Hematological MalignancySignal TransductionSignaling PathwayMixed-phenotype Acute LeukemiaReceptor Tyrosine Kinase	2002	596
In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase Carlos Garcı́a-Echeverrı́a, Mark Pearson, Andreas Marti, Cancer Cell Cancer ResearchMedicineReceptor Tyrosine KinaseVivo Antitumor ActivityNvp-aew541—a Novel	2004	535
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor Sauveur-Michel Maira, Sabina Pecchi, Alan Huang, Molecular Cancer Therapeutics PharmacotherapyDifferent Selectivity ProfileChemical BiologyPharmaceutical ChemistryTumor Biology	2011	524
PKC zeta is a molecular switch in signal transduction of TNF-alpha, bifunctionally regulated by ceramide and arachidonic acid. Gerhard Müller, Mohammed Akli Ayoub, Peter Störz, The EMBO Journal Signal TransductionMolecular PhysiologyBiochemistrySignaling PathwayNatural Sciences	1995	501

Page 1